Emerging Markets Collaborate to Succeed in Post-Pandemic World

What It Covers

A panel of biotech and pharma experts from Latin America, The Gulf, and Europe examines how pandemic-era collaboration models — spanning academia, government, and industry — can reshape emerging markets' biomanufacturing capabilities post-COVID.

Key Questions Answered

• •Collaboration velocity: During COVID-19, the industry recorded over 90 partnerships in a single year — a volume that previously took roughly two decades to accumulate. Policymakers and companies should use this benchmark to set baseline collaboration targets for future health preparedness planning.
• •Supply chain resilience: No country achieves 100% biopharmaceutical self-sufficiency, and pursuing it ties up capital inefficiently. Instead, regions should map critical dependencies across the full supply chain and build redundancy through multi-country partnerships rather than isolated domestic manufacturing expansion.
• •Emerging market strategy: Saudi Arabia bypassed the common "import bulk, finish locally" model by building an end-to-end innovation ecosystem before the pandemic hit. Emerging markets should prioritize full-process technology transfer and domestic IP ownership over last-step manufacturing to reduce external dependency.
• •Health literacy as policy priority: Vaccine misinformation spread partly because populations lack foundational health literacy. Policymakers should treat public science education as a core component of any health technology rollout strategy, not an afterthought, to protect the value of innovation investment.